Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00185692 · ClinicalTrials.gov registry record · Phase 2
Allogeneic Transplantation From Related Haploidentical Donors
A Phase 2 study of Leukemia and Graft-Versus-Host Disease, sponsored by Stanford University.
- Completed
- Registry status
- Phase 2
- Development phase
- 16
- Enrollment target
- 1
- Study location
NCT00185692 is a Phase 2 study of Leukemia and Graft-Versus-Host Disease that has completed, run by Stanford University. The registered enrollment target is 16 participants, below the 487-participant average among 233 other Leukemia trials with a reported enrollment target (97% lower). The trial reports 1 study location across 1 state.
The verdict
NCT00185692, a Phase 2 study of Leukemia and Graft-Versus-Host Disease, has completed, sponsored by Stanford University.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 16 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of the study is to evaluate the feasibility and safety of transplanting CD34+ selected hematopoietic cells from a haploidentical related donor following a nonmyeloablative regimen of total lymphoid irradiation (TLI) and antithymocyte globulin (ATG).
Conditions Studied
Interventions
- DRUG G-CSF
- DRUG Mycophenolate Mofetil
- DRUG Cyclosporine
- PROCEDURE non-myeloablative hematopoietic cell transplantation
- DRUG Anti-Thymocyte Globulin
Study Locations (1)
California
- Stanford University School of Medicine - Stanford
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 16 participants |
| Start Date | 2000-08 |
| Est. Completion | 2010-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00185692
The ClinicalTrials.gov registry entry for NCT00185692 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 16 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 487-participant average among 233 other Leukemia trials with a reported enrollment target (97% lower). The listed sponsor is Stanford University, which has 1,744 total studies on file at ClinicalTrials.gov.
The record links to 8 conditions, with Leukemia appearing as the primary indexed condition, and to 5 interventions - of which G-CSF is the first listed.
NCT00185692 reports 1 study location spanning 1 distinct geographic area - top geographies include California.
Frequently Asked Questions
What is clinical trial NCT00185692 about?
NCT00185692 is a clinical study titled "Allogeneic Transplantation From Related Haploidentical Donors". The purpose of the study is to evaluate the feasibility and safety of transplanting CD34+ selected hematopoietic cells from a haploidentical related donor following a nonmyeloablative regimen of total lymphoid irradiation (TLI) and antithymocyte globulin (ATG).
What is the current status of trial NCT00185692?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 16 participants. The study started on 2000-08. Estimated completion is 2010-12.
What conditions does trial NCT00185692 study?
This clinical trial studies the following conditions: Leukemia, Graft-Versus-Host Disease, MDS, Hodgkin's Disease, Blood Cancer.
What interventions are being tested in trial NCT00185692?
The interventions under investigation include: G-CSF (DRUG), Mycophenolate Mofetil (DRUG), Cyclosporine (DRUG), non-myeloablative hematopoietic cell transplantation (PROCEDURE), Anti-Thymocyte Globulin (DRUG).
Who is sponsoring clinical trial NCT00185692?
This trial is sponsored by Stanford University, which has 1,744 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00185692 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Leukemia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Evaluation of Two Dose Levels of Quizartinib as Maintenance in FLT3-ITD (+) Acute Myeloid Leukemia Patients in Complete Remission
RECRUITING · Phase 2
-
Time-limited Triplet Combination of Pirtobrutinib, Venetoclax, and Obinutuzumab for Patients With Treatment-naïve Chronic Lymphocytic Leukemia (CLL) or Richter Transformation (RT)
RECRUITING · Phase 2
-
Study of Pedi-cRIB: Mini-Hyper-CVD With Condensed Rituximab, Inotuzumab Ozogamicin and Blinatumomab (cRIB) for Relapsed Therapy for Pediatric With B-Cell Lineage Acute Lymphocytic Leukemia
RECRUITING · Phase 2
-
Cladribine Plus Low Dose Cytarabine (LDAC) Alternating With Decitabine in Patients With Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS)
RECRUITING · Phase 2
-
Dose-Expansion Study of Low Dose Post-Transplant Cyclophosphamide/Tacrolimus/Ruxolitinib for Graft-versus-Host Disease (GVHD) Prophylaxis in Myeloablative Allogeneic Peripheral Blood Stem Cell Transplantation
RECRUITING · Phase 2
-
A Phase II Study of the Menin Inhibitor Revumenib in Leukemia Associated With Upregulation of HOX Genes
RECRUITING · Phase 2
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.